FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Syndicate content

Eisai related Press Releases

Nobelpharma and Eisai Announce Japan Launch of Anticonvulsant Agent Fostoin® 750 mg for Injection

Posted January 17, 2012

FOR IMMEDIATE RELEASEJanuary 16, 2012Nobelpharma Co., Ltd. Eisai Co., Ltd.Nobelpharma and Eisai Announce Japan Launch of Anticonvulsant Agent Fostoin® 750 mg for Injection Nobelpharma Co., Ltd. Read more...

Eisai to Acquire Global License to ChemAxon Software for Drug Discovery Infrastructure

Posted January 9, 2012

Eisai to Acquire Global License to ChemAxon Software for Drug Discovery Infrastructure January 03, 2012 BUDAPEST, Hungary, & TOKYO--(BUSINESS WIRE)--Patcore, Inc., an exclusive agency for Read more...

Eisai to Acquire Global License to ChemAxon Software for Drug Discovery Infrastructure

Posted January 3, 2012

BUDAPEST, Hungary, & TOKYO--(BUSINESS WIRE)-- Patcore, Inc., an exclusive agency for ChemAxon in Japan, confirms the global licensing of ChemAxon’s JChem Cartridge for Oracle to Eisai Co. The Read more...

Eisai to accelerate late-stage clinical development of new drugs by effectively leveraging external resources

Posted September 7, 2011

-Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib)- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") Read more...

Eisai discontinues development of Pariet/Aciphex extended-release capsules, 50 mg

Posted September 2, 2011

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the company has decided to terminate development of its investigational proton pump inhibitor (PPI), Read more...

U.S. FDA Provides Response to Perampanel New Drug Application

Posted July 29, 2011

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Read more...

SuperGen Completes Acquisition of Astex Therapeutics

Posted July 20, 2011

DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction Read more...

Following Its Launch as Adjunctive Therapy for the Treatment of Partial-Onset Epileptic Seizures, Valeant/GlaxoSmithKline’

Posted May 19, 2011

Eisai’s Perampanel is Also Forecasted to Earn Peak Year Sales of up to $250 Million, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the Read more...

Epizyme to Present at MassBio Annual Meeting

Posted March 17, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced that Read more...

Eisai Phase III Study for Eritoran Does Not Meet Primary Endpoint

Posted January 25, 2011

Eisai Does Not Plan to Submit Marketing Authorization Applications to Regulatory Authoritiesby Fiscal Year-End 2010 Woodcliff Lake, NJ, January 25, 2011 - Based on the preliminary findings from the Read more...
1234next ›last »